 The focus of much CF gene therapy research is aimed at trying to place a normal copy of the "CFTR" gene into affected cells.Transferring the normal "CFTR" gene into the affected epithelium cells would result in the production of functional CFTR protein in all target cells, without adverse reactions or an inflammation response.To prevent the lung manifestations of CF, only 5–10% the normal amount of CFTR gene expression is needed.